ANNX Annexon, Inc. Insider Trading

Director Muneer Satter bought 613,497 shares of ANNX at $5.41, increasing holdings to 10.34M; his prior 5 ANNX buys all showed positive 90d returns.

Muneer Satter, a Director, purchased 613,497 shares of Annexon at $5.41 on 2026-05-28 for $3,319,018.77, expanding his holdings by 6.3% to 10.34M shares. His prior trades at ANNX demonstrate a strong pattern: all 5 previous buys exhibited positive 90-day returns, ranging from +13.0% to +63.6%, with a 90d win rate of 100% at this ticker. The current stock price of $5.42 sits 24.5% below its 52-week high of $7.18, suggesting this purchase occurred in a depressed valuation environment relative to recent trading levels. However, the company remains unprofitable with a net income of -$44.1M over its most recent full fiscal year, so the fundamental backdrop remains challenged despite the insider's continued accumulation pattern.

Director Carson William H. adds 8,000 shares to growing stake in money-losing biotech amid 52-week high pullback; repeat buyer with mixed near-term timing.

Carson William H., a director at Annexon, is making his sixth open-market purchase of the company's stock in 36 months, buying 8,000 additional shares while the stock trades notably below its 52-week high and amid a recent one-month decline. This purchase builds on a pattern of consistent accumulation at this ticker—he has been a repeat buyer with no sales—but his prior purchases at Annexon show mixed results: four of five prior acquisitions saw the stock gain within 30 days, though only two showed gains over a 90-day window, with three facing declines. More broadly, Carson has completed 18 open-market purchases across all his holdings over the past three years with no sales, suggesting a habitual buyer's stance, though the inconsistent returns on his Annexon purchases suggest his timing here has been uneven. The company itself is unprofitable, burning cash with losses in both the most recent quarter and full-year results, making this a bet on a struggling biotech rather than a financially stable operation. The combination of a director's continued commitment to accumulation at depressed prices, paired with a track record of mixed execution and a company in preclinical distress, presents a mixed signal: persistence of conviction mitigated by evidence of poor near-term market timing on prior Annexon buys.

Director William H. Carson buys 8,000 shares of ANNX at $6.20; stock down -16.7% from 52-week high, company unprofitable (-$54.9M net income).

Carson purchased 8,000 shares at $6.20 on 2026-04-10, increasing his holdings from 62,405 to 70,405 shares (+12.8%). The purchase occurs at a material discount to the 52-week high ($6.96), though the stock is currently trading at $5.80, suggesting the transaction has already moved against the position. This purchase follows a consistent pattern: across his prior 5 trades in ANNX, Carson has demonstrated strong timing discipline—3 of 4 prior measurable buys achieved positive 90-day returns, with the strongest prior buy (2025-10-30) returning +98.4% over 90 days. His cross-ticker track record shows 16 prior buys averaging +24.2% over 90 days with a 66.67% win rate. However, the company's fundamental position is deteriorating: net income was -$54.9M over the most recent full fiscal year, and the 90-day price action is negative (-13.2%), contradicting the positive momentum observed in earlier purchases. The director's continued accumulation despite unprofitability and recent weakness warrants attention as a divergence between his historical timing success and present market conditions.

Director Carson William H. buys 8,000 shares of ANNX at $5.67; fourth consecutive purchase in 6 months despite $-54.9M net loss.

Carson William H. purchased 8,000 shares at $5.67 on 2026-03-10, increasing his holdings by 14.7% to 62.4K shares. This marks his fourth consecutive open-market buy at Annexon in the past six months (prior buys on 2025-12-30, 2025-12-01, and 2025-10-30), demonstrating persistent accumulation despite the company's unprofitable status—net income of $-54.9M for the most recent full fiscal year. His same-ticker purchase history shows strong outcomes: the three prior purchases with measurable 90-day windows delivered returns of 25.3%, 98.4%, and 63.9%, and 4 of 4 prior buys at this ticker were well-timed at the 90-day mark. The current price of $5.44 represents a -3.0% decline over 30 days and -21.8% from the 52-week high, creating the backdrop for this purchase. The pattern of sustained insider buying into operational losses and recent weakness, paired with his proven accuracy in prior timing at this ticker, presents a noteworthy signal for continued investor monitoring.

Director Carson William H. buys 4,115 shares of ANNX at $5.02; 5th consecutive purchase, stock now -14.7% from 52-week high

Carson William H. purchased 4,115 shares at $5.02 on 2025-12-30, expanding his holdings to 54,405 shares. This is the fifth consecutive open-market buy at ANNX within the past five months, with prior purchases occurring on 2025-12-01, 2025-10-30, 2025-09-30, 2025-09-02, and 2025-07-30. At the 90-day measurement window, three of his three prior buys at this ticker delivered positive returns (63.9%, 97.6%, and 42.0%), indicating a pattern of well-timed entry points. The company reported negative net income of $-54,922,000.00 over its most recent full fiscal year, yet the director has continued accumulating shares as the stock recovered 47.0% over 90 days from a 52-week low of $1.38. The current price of $4.69 sits 14.7% below the 52-week high, suggesting the director is purchasing during a pullback rather than at peak valuations.

Director Carson William H. bought 4,115 shares of ANNX at $4.47; cluster pattern with 2 other insiders buying within 14 days; 3 of 3 prior buys at ANNX well-timed at 90-day mark.

Carson William H., a director at Annexon, purchased 4,115 shares at $4.47 on 2025-12-01, increasing his holdings by 8.9% to 50,290 shares. This purchase occurs as part of a broader insider cluster: 2 other insiders also bought within the past 14 days, suggesting coordinated conviction at current price levels. His prior transaction history at ANNX demonstrates strong timing discipline—3 of 3 prior buys showed positive 90-day returns (ranging from +37.0% to +97.6%), indicating a pattern of accumulating ahead of sustained rallies. The 30-day and 90-day returns post-purchase (+35.0% and +99.1% respectively) align with his historical success at this ticker. However, the company remains unprofitable with net income of $-54,922,000.00 and a market cap of $165,052,058.20, so fundamental risk remains material even as the price action validates prior entry decisions.

Director Choi Jung buys 33,000 shares of ANNX at $4.19 amid cluster pattern; company posted $-54.9M loss

Choi Jung, a Director, purchased 33,000 shares at $4.19 on 2025-12-01, establishing a new position worth $138,270.00. This purchase is part of a cluster pattern with 2 other insiders buying within the same 14-day window, suggesting coordinated interest in the stock. Notably, the purchase price of $4.19 is slightly below the current price of $4.28, and the stock has recovered 99.1% over the past 90 days—a substantial rebound from depressed levels. However, the company remains unprofitable with a full-year net income of $-54.9M against a market cap of $165.1M, indicating significant ongoing financial stress. The insider buying cluster during a period of recent stock recovery and amid fundamental operating losses warrants attention to whether this represents management's view of intrinsic value or other considerations.

Director Satter Muneer A bought 822,613 shares over 2 days at avg $4.38; now holds 9.73M shares (+9.2%)

Director Muneer A Satter executed 2 separate purchases totaling 822,613 shares for $3,600,783.64 on 2025-11-20 and 2025-11-21, increasing his holdings by 9.2% to 9,728,637 shares. The purchases occurred at $4.48 and $4.28 per share, with a blended average of $4.38—just 2.3% above the current price of $4.27. The stock is currently trading 22.4% below its 52-week high of $5.50 but has gained 42.3% over the past 30 days and 84.8% over 90 days, suggesting a recent recovery from depressed levels. Annexon is unprofitable with net income of $-54,922,000 over its most recent full fiscal year, a material concern that contextualizes any accumulation activity. The director's timing warrants observation given the proximity of these purchases to the current price and the stock's recent sharp gains.

Director Satter Muneer A bought 1,500,000 shares at $2.99–$3.94 over 3 days; holds 8.91M shares post-transaction.

Satter Muneer A (Director) executed 3 separate open-market purchases totaling 1,500,000 shares for $5,055,000.00 over November 17–19, 2025, increasing his holdings by 20.3% to 8.91M shares. The transactions were completed at prices ranging from $2.99 to $3.94, with a blended average of $3.37, ahead of the current price of $4.06. Annexon trades 35.9% below its 52-week high of $6.33 and the company reported negative net income of $-54,922,000.00 over its most recent fiscal year. The insider's cross-ticker track record shows 1 prior buy with 100% 90-day win rate and an average 90-day return of +130.6%; his single prior purchase at ANNX (on 2023-12-26) achieved a 90-day return of +130.6%, demonstrating historical pattern success at this ticker.

Director Carson William H. buys 4,115 ANNX shares at $3.17; stock now $3.16, down 58.3% from 52-week high of $7.57.

Carson William H. purchased 4,115 shares at $3.17 on 2025-10-30, expanding his holdings by 9.8% to 46,175 shares total. The purchase occurred at a significant discount to the 52-week high of $7.57, though current price of $3.16 shows the stock has appreciated 4.3% over the past 30 days and 29.0% over 90 days. At the same ticker, his prior buy on 2025-07-30 demonstrated a positive 90-day outcome (+42.0%), and his cross-ticker track record shows a 60.00% 90-day win rate across 12 prior buys with average 90-day returns of 7.9%. However, Annexon remains fundamentally unprofitable with $-49.2M net income against a $121.9M market cap, warranting scrutiny of whether recent price recovery reflects genuine operational progress or temporary momentum in a distressed equity.